BioPharma Credit - The silent yield specialist in the life science sector

BioPharma Credit has spent the last five years evolving from a niche yield vehicle trading persistently below NAV into a higher‑yielding, more actively managed debt platform serving life‑science companies. Over this period, the share price has cycled through COVID weakness, a prolonged discount "value trap" phase, and a recent recovery driven by rising rates, increased portfolio activity, and share buybacks. The investor narrative has shifted from "steady but dull income trust on a structural discount" to "high‑yield, specialist credit with active discount control, though subject to borrower‑specific risks (notably LumiraDx)."

Below, "last five years" spans roughly 2020 to early 2025.

---

2020–2021: COVID shock and income trust

During 2020, the COVID‑19 shock rippled through risk assets and listed investment trusts, and BioPharma Credit's shares traded at a marked discount to NAV despite the underlying portfolio comprising largely secured, long‑term life‑sciences loans. The trust continued paying quarterly dividends of at least 1.75 cents per share (a pattern established from mid‑2018), which anchored the income story but proved insufficient to close the discount during pandemic turbulence.

Narrative and perception (2020–21)

The stock settled into the investor mind as a defensive, income‑oriented credit vehicle: stable cashflows, low correlation to traditional equities, but limited growth and structurally constrained liquidity. Among UK closed‑end fund investors, it increasingly occupied the "yield plus discount" category rather than a growth or biotech play, contributing to its value‑style, somewhat overlooked profile.

Technical phase (2020–21)

Price data show the stock trading in a relatively tight band around the high‑80s to low‑90 cents, consistent with a prolonged sideways pattern after the initial COVID drawdown. Rallies toward NAV repeatedly stalled as the discount persisted. Trading volumes were modest, with moves mainly reflecting discount oscillations rather than NAV shocks, producing a mean‑reverting range‑trade pattern rather than the behaviour of a trending stock.

---

2022: Discount persists, macro turns

Into 2022, the portfolio remained anchored in senior secured loans to life‑science issuers, and the trust maintained its dividend target. Yet shares continued trading below NAV as broader pressure on alternative income funds mounted alongside rising rates and risk‑free yields. The life‑sciences financing model came under greater scrutiny as higher rates and tighter capital markets made refinancing harder for some borrowers, sharpening investor focus on individual credits.

Narrative and perception (2022)

The narrative shifted toward "cheap yield but potentially a value trap," with investors concerned that a persistent discount, coupled with pockets of borrower‑specific risk, could erode total returns despite solid reported income. Specialist followers still saw it as a relatively defensive way to access life‑science upside through debt rather than equity. However, generalist income investors increasingly favoured simpler, higher‑liquidity credit vehicles as yields rose across markets.

Technical phase (2022)

The chart through this period shows the stock remaining mostly range‑bound below stated NAV, around 0.90–0.93, with failed attempts to sustain moves closer to NAV as macro headwinds and sector sentiment weighed. Drawdowns in percentage terms were material for a "cash‑like" credit vehicle but shallow compared with equities, reinforcing the low‑beta, income‑trust trading pattern.

---

2023: Borrower issues and risk focus

By 2023, underlying borrowers—including LumiraDx and others—featured more prominently in commentary as credit spreads and refinancing risk increased, raising questions about loan recoveries and potential impairments. Income remained strong nonetheless; net income per share for 2023 reached 8.28 cents, supporting the continuation of quarterly dividends of at least 1.75 cents per share.

Narrative and perception (2023)

The narrative tilted toward "specialist credit with idiosyncratic borrower risk," as investors began focusing on whether problem credits could dent NAV and distributions rather than questioning the strategy itself. Some investors started framing BPCR as a potential "turnaround yield trust" if management could successfully navigate troubled loans and deploy the discount for accretive share buybacks.

Technical phase (2023)

The stock experienced episodes of weakness when borrower‑specific headlines emerged, widening the discount and producing short downtrends within the broader range, though without prolonged collapse. These drawdowns were followed by stabilisation as dividend visibility and NAV updates reassured investors, generating repeated bounces back into the high‑80s/low‑90s cents band.

---

2024: High activity, LumiraDx resolution, buybacks

2024 proved an "active year": BPCR and subsidiaries committed $994.1 million to seven new transactions while collecting $750.2 million in repayments (from Akebia, Coherus, Immunocore, ImmunoGen, and LumiraDx) plus $17.4 million in prepayment and make‑whole fees, locking in attractive returns on exited positions. The company deployed $435 million into four new deals (Alphatec, Geron, Novocure, Tarsus) and refinanced $369.1 million with existing borrowers (UroGen, Collegium, Insmed), funding additional tranches to Collegium and Insmed, and closed the year with total net assets of $1,181.7 million.

Key results and distributions (2024)

BPCR generated net income per share of 9.99 cents for 2024, up from 8.28 cents in 2023, and paid 10.18 cents in dividends (3 cents above its annual target), followed by a Q4 2024 dividend of 2.89 cents per share (including 1.14 cents special) paid in February 2025. NAV per share declined modestly from 102.93 cents to 99.63 cents (–3%) even as the share price rose from 84.0 cents to 88.4 cents, narrowing the discount and bolstered by income growth, capital deployment, and confidence in recoveries.

LumiraDx and risk clean‑up (2024)

A major overhang—the LumiraDx loan—was largely resolved; by year‑end, BPCR had recovered approximately 96% of invested capital, significantly de‑risking the portfolio and easing investor concerns around this position. This shift produced a clearer, more diversified portfolio narrative focused on secured loans, rather than one shadowed by a single problematic credit.

Narrative and perception (2024)

With rising net income, above‑target dividends, and vigorous deployment levels, the narrative evolved toward a more positive "specialist, high‑yield credit compounder" with demonstrated workout capability and strong deal flow. Substantial share buybacks under an updated discount control mechanism—some $106.7 million of shares repurchased in 2024—strengthened perceptions that management was actively closing the discount gap and aligned with shareholder interests.

Technical phase (2024)

The share price advanced from 84.0 cents at end‑2023 to 88.4 cents at end‑2024, a modest but meaningful uptrend for a credit‑oriented trust, particularly given the slight NAV decline. Trading repeatedly tested resistance near the low‑90s cents area (still below NAV), with improving volume and buyback support transforming the prior long sideways range into a gentle ascending channel.

---

Early 2025: High yield, consolidation near 0.90

Into early 2025, shares trade around 0.88–0.92, with a 52‑week range near 0.80–0.94 and a trailing dividend yield close to 10%, reflecting both sustained payouts and a still‑meaningful discount to NAV. The trust continues to present itself as a specialist debt provider to life‑sciences with an unbroken quarterly dividend record since mid‑2018 and a strong pipeline of lending opportunities.

Narrative and perception (2025 YTD)

The current narrative centres on a high‑yield, specialist credit trust where the pivotal questions are: can double‑digit yields sustain, how much further can deal quality support returns, and how tightly can discount control narrow the gap to NAV? Among UK closed‑end fund investors, BPCR is increasingly viewed as a credible "defensive income compounder," though it remains subject to sentiment shifts in alternative credit and life‑sciences risk.

Technical phase (2025 YTD)

Price action shows a tight consolidation zone just under 0.93, with multiple retests of that level since late 2024, suggesting a well‑defined resistance band where a breakout could align with further discount compression if sentiment improves. Daily volumes frequently exceed 1–2 million shares, reflecting active trading and buyback engagement. The chart now reads as an extended sideways‑to‑slightly‑rising range, a material departure from the deeper discount levels seen earlier in the five‑year window.